⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Glycopyrronium cloth

دستمال گلیکوپیرونیوم (تعریق زیر بغل)

⚠ Unverified

🧴 DermatologicalsTopical anticholinergic

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA210361 ATC D11AA01

Market / country: 🇺🇸 USA

Qbrexza (US)

🧮 Dose calculator

Disease / regimen

Axillary hyperhidrosis · Regimen source: FDA Qbrexza · 2 FDA Qbrexza · 1

⛔ On clean dry underarm skin only; wipe one cloth once across each underarm; no more than once every 24 h. Wash hands afterwards (blurred vision if it reaches the eyes). FDA Qbrexza · 2 FDA Qbrexza · 1

🛡️ Safety & information

Contraindications

⛔ Conditions worsened by anticholinergic effects: glaucoma, paralytic ileus, unstable cardiovascular status in haemorrhage, severe ulcerative colitis, toxic megacolon, myasthenia gravis, Sjögren’s. FDA Qbrexza · 4

Formulations

Single-use cloth with 2.4% glycopyrronium — cream 🇺🇸 USA FDA Qbrexza · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Qbrexza · 8.1
“Risk Summary There are no available data on Qbrexza use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Qbrexza · 8.2
“Risk Summary There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Qbrexza · 8.4
“The safety, effectiveness and pharmacokinetics of Qbrexza have been established in pediatric patients age 9 years and older for topical treatment of primary axillary hyperhidrosis [see Clinical Pharmacology ( 12.3 )] .”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Qbrexza · 8.5
“Clinical trials of Qbrexza did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA210361
DailyMed (FDA label)FDA Qbrexza
MedlinePlus (NIH)❌ None
WHO ATC/DDDD11AA01
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Qbrexza · 3 FDA Qbrexza · 2 FDA Qbrexza · 1 FDA Qbrexza · 4 FDA Qbrexza · SPL approval / marketing category FDA Qbrexza · 8.1 FDA Qbrexza · 8.2 FDA Qbrexza · 8.4 FDA Qbrexza · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified